Cargando…
1719. Pharmacokinetics (PK) of Oritavancin in Children: The ORKIDS Trial
BACKGROUND: Oritavancin (ORI) is a lipoglycopeptide antibiotic approved in adults as a single 1,200 mg intravenous (IV) dose for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by Gram-positive organisms, including methicillin-resistant Staphylococcus aureus. The...
Autores principales: | Bradley, John, Arrieta, Antonio, Bokesch, Paula, Fusaro, Karen, Griffith, David C, Loutit, Jeffrey S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252426/ http://dx.doi.org/10.1093/ofid/ofy209.125 |
Ejemplares similares
-
1676. PK, Safety and Tolerability of VABOMERE(®) (meropenem-vaborbactam) in Infants, Children and Adolescents
por: Bokesch, Paula M, et al.
Publicado: (2023) -
1387. Phase I Study to Evaluate the Safety and Pharmacokinetics (PK) of Single and Multiple Ascending Doses (SAD/MAD) of Intravenous (IV) Minocycline in Healthy Adult Subjects
por: Cornely, Oliver A, et al.
Publicado: (2018) -
A Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent With the Phase 3 SOLO Program
por: Redell, Mark, et al.
Publicado: (2018) -
1418. Pharmacokinetics (PK) and Toxicity of Intravenous Amikacin (AMK) Dosed Three Times a Week (TIW) for Treatment of Disseminated Mycobacterium abscessus Infection in Children
por: Tran, M Tuan, et al.
Publicado: (2018) -
1420. Successful Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin
por: Van Hise, Nicholas W, et al.
Publicado: (2019)